Drug Information

Drug General Information
Drug ID
D0N1UU
Former ID
DIB019448
Drug Name
compound 32
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530917]
Formula
C20H17Cl2N3O2
InChI
InChI=1S/C20H17Cl2N3O2/c21-13-3-1-11(2-4-13)15-9-23-10-16(15)20(27)25-18-7-12-5-6-24-19(26)14(12)8-17(18)22/h1-8,15-16,23H,9-10H2,(H,24,26)(H,25,27)/t15-,16+/m0/s1
InChIKey
XBFAFSAUQFDEOK-JKSUJKDBSA-N
PubChem Compound ID
46871820
PubChem Substance ID
99311455, 103061172, 103757131, 104154077, 249565864
Target and Pathway
Target(s) Protein kinase G (PKG) 2 Target Info Inhibitor [530917]
Rho associated protein kinase 2 Target Info Inhibitor [530917]
protein kinase N2 Target Info Inhibitor [530917]
KEGG Pathway cGMP-PKG signaling pathway
cAMP signaling pathway
Chemokine signaling pathway
Sphingolipid signaling pathway
Vascular smooth muscle contraction
Wnt signaling pathway
Axon guidance
Focal adhesion
Platelet activation
Leukocyte transendothelial migration
Regulation of actin cytoskeleton
Oxytocin signaling pathway
Pathogenic Escherichia coli infection
Shigellosis
Salmonella infection
Pathways in cancer
Proteoglycans in cancer
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Pathway Interaction Database RhoA signaling pathway
Plasma membrane estrogen receptor signaling
Osteopontin-mediated events
PLK1 signaling events
PAR4-mediated thrombin signaling events
PAR1-mediated thrombin signaling events
Signaling events mediated by focal adhesion kinase
Reactome EPHB-mediated forward signaling
EPHA-mediated growth cone collapse
G alpha (12/13) signalling events
Sema4D induced cell migration and growth-cone collapse
VEGFA-VEGFR2 Pathway
RHO GTPases Activate ROCKs
WikiPathways G13 Signaling Pathway
Regulation of Actin Cytoskeleton
Focal Adhesion
JAK/STAT
Spinal Cord Injury
Pathogenic Escherichia coli infection
Leptin signaling pathway
Semaphorin interactions
Integrin-mediated Cell Adhesion
GPCR downstream signaling
MicroRNAs in cardiomyocyte hypertrophy
Androgen receptor signaling pathway
References
Ref 530917Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9.
Ref 530917Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.